<DOC>
	<DOCNO>NCT00198432</DOCNO>
	<brief_summary>To evaluate best timing concomitant chemoradiotherapy among patient NSCLC stage III resectable treat concomitant chemo-radiotherapy , either precede induction chemotherapy , follow consolidation chemotherapy .</brief_summary>
	<brief_title>Chemoradiotherapy NSCLC Stage IIIB</brief_title>
	<detailed_description>Chemotherapy : C = Cisplatine : 80 mg/m² P = Paclitaxel : 200 mg/m² N = Vinorelbine : 15 mg/m² Radiotherapy : 66 Gy 33 fraction ( 2 Gy/fraction , 1 fraction/day , 6,5 week ) High energy Photons X ( &gt; = 9MV )</detailed_description>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>NSCLC stage IIIA N2 IIIB resectable , except N3 susclavicular , reach pleural PS = 0 1 Possibility include target one exposure field Slimming &lt; 10 % weight body Functions hepatic , renal hematologic normal VEMS &gt; 40 % PaO2 &gt; 60 mmHg write sign informed consent Exclusion criterion : NSCLC stage IV wetIIIB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>